A Prospective Pharmacodynamic Study of Rivaroxaban
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The ability to explain bleeding or clotting complications in patients treated with
rivaroxaban remains challenging. In addition, there is limited data on how coagulation tests
perform in patients treated with therapeutic doses of rivaroxaban. Predicted responses of
coagulation tests to therapeutic doses of rivaroxaban may be helpful in better understanding
abnormal responses to rivaroxaban. The purpose of the study is to define a therapeutic
reference range for peak and trough coagulation tests in patients taking FDA approved doses
of rivaroxaban and to determine which tests may be most clinically useful for monitoring
rivaroxaban.